Intuitive Surgical (NASDAQ:ISRG) Given New $540.00 Price Target at Raymond James

Intuitive Surgical (NASDAQ:ISRG) had its target price raised by Raymond James from $500.00 to $540.00 in a report issued on Monday morning, Benzinga reports. The brokerage currently has an outperform rating on the medical equipment provider’s stock.

Other equities research analysts have also issued reports about the company. Barclays raised their price target on Intuitive Surgical from $430.00 to $490.00 and gave the stock an overweight rating in a research note on Thursday, July 18th. Truist Financial lifted their target price on Intuitive Surgical from $520.00 to $570.00 and gave the company a buy rating in a research report on Monday. Citigroup lifted their target price on Intuitive Surgical from $512.00 to $560.00 and gave the company a buy rating in a research report on Thursday, August 22nd. Piper Sandler lifted their target price on Intuitive Surgical from $490.00 to $495.00 and gave the company an overweight rating in a research report on Friday, July 19th. Finally, JPMorgan Chase & Co. lifted their price target on Intuitive Surgical from $495.00 to $575.00 and gave the company an overweight rating in a report on Friday. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat, Intuitive Surgical currently has an average rating of Moderate Buy and a consensus price target of $467.55.

Intuitive Surgical Stock Performance

ISRG stock opened at $487.61 on Monday. Intuitive Surgical has a fifty-two week low of $254.85 and a fifty-two week high of $496.48. The business’s 50-day moving average is $481.33 and its two-hundred day moving average is $435.81. The company has a market cap of $172.96 billion, a price-to-earnings ratio of 88.02, a P/E/G ratio of 5.40 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last released its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the business posted $1.18 earnings per share. Equities analysts predict that Intuitive Surgical will post 5.22 earnings per share for the current year.

Insider Activity

In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $446.60, for a total transaction of $167,921.60. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at $2,458,979.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Robert Desantis sold 376 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $446.60, for a total value of $167,921.60. Following the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,458,979.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Myriam Curet sold 2,818 shares of the stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $1,291,010.34. Following the completion of the sale, the executive vice president now owns 298 shares in the company, valued at approximately $136,522.74. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,120 shares of company stock worth $25,528,753 over the last ninety days. Corporate insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

Hedge funds have recently made changes to their positions in the company. Mirador Capital Partners LP grew its holdings in shares of Intuitive Surgical by 1.4% during the third quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider’s stock worth $1,732,000 after purchasing an additional 50 shares during the last quarter. Advisors Asset Management Inc. grew its holdings in shares of Intuitive Surgical by 18.1% during the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider’s stock worth $2,945,000 after buying an additional 1,129 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in shares of Intuitive Surgical by 617.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider’s stock worth $39,622,000 after buying an additional 76,649 shares during the last quarter. Brookstone Capital Management grew its holdings in shares of Intuitive Surgical by 22.4% during the second quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider’s stock worth $5,340,000 after buying an additional 2,289 shares during the last quarter. Finally, M&G Plc grew its holdings in shares of Intuitive Surgical by 53.5% during the second quarter. M&G Plc now owns 5,069 shares of the medical equipment provider’s stock worth $2,256,000 after buying an additional 1,766 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.